ArticleSchizophrenia bulletin2026
Delayed Diabetes Treatment and Persistent Hyperglycemia among Individuals with Schizophrenia: a Nationwide Register-Based Study.
Article in Schizophrenia bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
background and hypothesisIndividuals with schizophrenia are at increased risk of type 2 diabetes and diabetes-related complications. Whether the detection of hyperglycemia in individuals with schizophrenia is followed by timely clinical action remains insufficiently understood. We hypothesized that glucose-lowering drug (GLD) treatment would be initiated later in individuals with schizophrenia with elevated glycated hemoglobin (HbA1c) than in matched individuals without schizophrenia, and that this delay would be reflected in worse HbA1c trajectories. STUDY
designWe identified all individuals with schizophrenia aged ≥30 years at the time of the first elevated HbA1c (≥48 mmol/mol) in nationwide Danish registers. These individuals were matched on age, sex, year of elevated HbA1c, and baseline HbA1c with up to five individuals without schizophrenia. In the year following the detection of elevated HbA1c, we compared time to GLD treatment between individuals with and without schizophrenia using a Cox proportional hazard model. Mean HbA1c levels over time were illustrated graphically and compared using linear mixed-effects models. STUDY
resultsWe identified 1527 individuals with schizophrenia and 7492 matched comparison individuals. In the year following detection of elevated HbA1c, schizophrenia was associated with a slower rate of GLD treatment initiation (hazard rate ratio [HRR] = 0.88, 95% confidence interval [CI]: 0.81-0.94). Consistently, HbA1c decreased more slowly among individuals with schizophrenia. Notably, schizophrenia was associated with a slower rate of GLD treatment initiation among males (HRR = 0.82, 95%CI: 0.74-0.90) but not females (HRR = 0.99, 95%CI: 0.87-1.11).
conclusionsSchizophrenia was associated with a slower rate of GLD treatment initiation and slower reductions in HbA1c following detection of elevated HbA1c, particularly among males.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.